What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Andrew W. Roberts focuses on Cancer research, Leukemia, Venetoclax, Immunology and Internal medicine.
His Cancer research research is multidisciplinary, incorporating perspectives in Mutation, Apoptosis, Signal transduction and Molecular biology.
His studies in Leukemia integrate themes in fields like breakpoint cluster region, Navitoclax, In vivo and Imatinib mesylate.
His studies deal with areas such as Cancer, Refractory Chronic Lymphocytic Leukemia, Pharmacology and Rituximab as well as Venetoclax.
His research in Immunology intersects with topics in Progenitor cell and SOCS3.
His Internal medicine study combines topics from a wide range of disciplines, such as Endocrinology, Oncology and B cell.
His most cited work include:
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Venetoclax, Cancer research, Immunology and Oncology.
His Internal medicine research integrates issues from Gastroenterology and Surgery.
In his study, which falls under the umbrella issue of Venetoclax, Myeloid is strongly linked to Myeloid leukemia.
His work deals with themes such as Apoptosis, B cell, Lymphoma, Leukemia and MCL1, which intersect with Cancer research.
His Leukemia research is multidisciplinary, relying on both Cancer, Navitoclax, In vivo, Mutation and Pharmacology.
The various areas that Andrew W. Roberts examines in his Immunology study include Progenitor cell and Haematopoiesis.
He most often published in these fields:
- Internal medicine (73.50%)
- Venetoclax (57.64%)
- Cancer research (45.84%)
What were the highlights of his more recent work (between 2018-2021)?
- Venetoclax (57.64%)
- Internal medicine (73.50%)
- Cancer research (45.84%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Venetoclax, Internal medicine, Cancer research, Oncology and Chronic lymphocytic leukemia.
Leukemia covers Andrew W. Roberts research in Venetoclax.
In general Internal medicine, his work in Hematology, Rituximab and Neutropenia is often linked to In patient linking many areas of study.
He combines subjects such as Mutation, Tyrosine kinase, Bruton's tyrosine kinase, B cell and MCL1 with his study of Cancer research.
His Oncology study integrates concerns from other disciplines, such as Relapsed refractory and Lymphocytic leukaemia.
His study in Chronic lymphocytic leukemia is interdisciplinary in nature, drawing from both Hematopoietic stem cell transplantation, Targeted therapy, Fludarabine and Single agent.
Between 2018 and 2021, his most popular works were:
- Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. (129 citations)
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. (94 citations)
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. (94 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
His primary areas of investigation include Venetoclax, Internal medicine, Cancer research, Leukemia and Oncology.
The subject of his Venetoclax research is within the realm of Chronic lymphocytic leukemia.
His work in Internal medicine tackles topics such as Neoplasm which are related to areas like Follicular lymphoma, Mutation and Missense mutation.
His work investigates the relationship between Cancer research and topics such as Mutation that intersect with problems in Plasma protein binding, Apoptosis, Mutant and Binding site.
The study incorporates disciplines such as Drug resistance and B cell in addition to Leukemia.
Andrew W. Roberts studied Myeloid leukemia and Myeloid that intersect with Myeloid Cell Leukemia Sequence 1 Protein, Bone marrow and MCL1.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
